Matches in Nanopublications for { ?s <http://purl.org/dc/terms/description> ?o ?g. }
- NP32746.RABy6Go1HLxgn-NIpNi2DBVaRy_GukvlKGrQML8aNTvmM130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32746.RABy6Go1HLxgn-NIpNi2DBVaRy_GukvlKGrQML8aNTvmM130_provenance.
- NP32735.RArXCD9oT0NF00NVJHcpI788tCT-z8gra9rTQfLgnLQr4130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32735.RArXCD9oT0NF00NVJHcpI788tCT-z8gra9rTQfLgnLQr4130_provenance.
- NP32736.RApfXmb_TPJahu_S3p1dlCxqpONDYzcYGMvbkl4AwVbLs130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32736.RApfXmb_TPJahu_S3p1dlCxqpONDYzcYGMvbkl4AwVbLs130_provenance.
- NP32738.RAjT0TrBLV3tYclN1HpHZSJ3alCPfRQlA2swQgyIROugM130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32738.RAjT0TrBLV3tYclN1HpHZSJ3alCPfRQlA2swQgyIROugM130_provenance.
- NP32741.RArfSAAHiyMnKsPuSSwMOE10LjRAv4ZQuZvCStS_9Zv4Q130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32741.RArfSAAHiyMnKsPuSSwMOE10LjRAv4ZQuZvCStS_9Zv4Q130_provenance.
- NP32744.RAovlHT3ixcA94L2RpFup2SglgBZccJsDLda6ZunA1hbc130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32744.RAovlHT3ixcA94L2RpFup2SglgBZccJsDLda6ZunA1hbc130_provenance.
- NP32747.RAv5L4PVbZg0gQEM5Oe2Jv9yVCxJelgmegmn3usU9Al-k130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32747.RAv5L4PVbZg0gQEM5Oe2Jv9yVCxJelgmegmn3usU9Al-k130_provenance.
- NP32742.RAFMUMHpdK_8pI22mNH4oViZNt5HfN-Tr8Bg3mIRHU6Bs130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32742.RAFMUMHpdK_8pI22mNH4oViZNt5HfN-Tr8Bg3mIRHU6Bs130_provenance.
- NP32743.RAJ2EFvcooayDFHeaQQr6fK65FzVamcNwuL17PpBHINX8130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32743.RAJ2EFvcooayDFHeaQQr6fK65FzVamcNwuL17PpBHINX8130_provenance.
- NP32737.RA9JjBCiFaorf9NuME_epupGFafriAbcFQ5TxCiNhU4Ug130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32737.RA9JjBCiFaorf9NuME_epupGFafriAbcFQ5TxCiNhU4Ug130_provenance.
- NP32739.RA8-y6aRZQ837Fq0KVqglWGI9xKlA_bB_syELC4Kxyj6M130_assertion description "[The early molecular processes underlying the neurological manifestations of an animal model of Wilson's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32739.RA8-y6aRZQ837Fq0KVqglWGI9xKlA_bB_syELC4Kxyj6M130_provenance.
- assertion description "[C3, prekallikrein, total kininogen, high molecular weight kininogen (HK), alpha-2-macroglobulin and factor XII were not significantly different in HAE patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Our results suggest that the A2M deletion polymorphism may not be a definitive risk factor of CAA in the elderly, although further study with larger samples is necessary to confirm this.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP266891.RAb2LaR6ru_ic44uA9Zvw16MrMzp9ewKMO81unxut1qns130_assertion description "[Our results suggest that the A2M deletion polymorphism may not be a definitive risk factor of CAA in the elderly, although further study with larger samples is necessary to confirm this.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP266891.RAb2LaR6ru_ic44uA9Zvw16MrMzp9ewKMO81unxut1qns130_provenance.
- NP217270.RAoga-09_xTMPdJqjetJaD1GpeocK5us0QVCocZA1I5Jk130_assertion description "[Our results suggest that the A2M deletion polymorphism may not be a definitive risk factor of CAA in the elderly, although further study with larger samples is necessary to confirm this.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217270.RAoga-09_xTMPdJqjetJaD1GpeocK5us0QVCocZA1I5Jk130_provenance.
- assertion description "[Cotransfection experiments indicated that the up- or downregulation of LAP, cathepsin B, and alpha 2-M observed in keratoconus-affected corneas was not mediated by Sp1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP292309.RAS2vjcAk0fRgBvSXXaw3Qsbngmz19AtWhbei3SNdtm_c130_assertion description "[Cotransfection experiments indicated that the up- or downregulation of LAP, cathepsin B, and alpha 2-M observed in keratoconus-affected corneas was not mediated by Sp1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP292309.RAS2vjcAk0fRgBvSXXaw3Qsbngmz19AtWhbei3SNdtm_c130_provenance.
- NP217222.RA78i2k2R6CV3TZAqOOteGcxQHLdLM2KZw-tyW9UQYxps130_assertion description "[Cotransfection experiments indicated that the up- or downregulation of LAP, cathepsin B, and alpha 2-M observed in keratoconus-affected corneas was not mediated by Sp1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217222.RA78i2k2R6CV3TZAqOOteGcxQHLdLM2KZw-tyW9UQYxps130_provenance.
- NP325671.RA1tTx-YIEtvggshugj6gMwmYYNwpwEvxM3wXjTEK29jo130_assertion description "[Cotransfection experiments indicated that the up- or downregulation of LAP, cathepsin B, and alpha 2-M observed in keratoconus-affected corneas was not mediated by Sp1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP325671.RA1tTx-YIEtvggshugj6gMwmYYNwpwEvxM3wXjTEK29jo130_provenance.
- assertion description "[Interestingly, plasma alpha(2)M from two DD patients showed markedly increased TGF-beta1 binding.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Interestingly, plasma alpha(2)M from two DD patients showed markedly increased TGF-beta1 binding.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP5242.RA8ToZa3mZk6DuDJGD9dN01LP_mTW81VfPO9_EJ_DHjW8130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP5242.RA8ToZa3mZk6DuDJGD9dN01LP_mTW81VfPO9_EJ_DHjW8130_provenance.
- NP44756.RA35sfqctXPaySeHCmvOuvIpJKI-NUeUAZib6SVP2arCk130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP44756.RA35sfqctXPaySeHCmvOuvIpJKI-NUeUAZib6SVP2arCk130_provenance.
- NP5246.RAhuQIOFyN1NTjC2WtukKwlu9vtcT2ckBRZXfSdqcOK-8130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP5246.RAhuQIOFyN1NTjC2WtukKwlu9vtcT2ckBRZXfSdqcOK-8130_provenance.
- NP59312.RAZAIQ9QtLBXlh8Wfd-OrsHiQrvvJ7evGoddlTTGXnMzY130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP59312.RAZAIQ9QtLBXlh8Wfd-OrsHiQrvvJ7evGoddlTTGXnMzY130_provenance.
- NP59313.RAarWM12EV3mUZYtmNLhXGGy7_5OmPcMFmxwwo8Q3-ajE130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP59313.RAarWM12EV3mUZYtmNLhXGGy7_5OmPcMFmxwwo8Q3-ajE130_provenance.
- NP44615.RAHJ1327nq7gJkn0H6TG4JJgyI8evpg76sOFVjy2uXU_k130_assertion description "[Distinctive immunohistochemical staining for alpha(2)M could be consistently demonstrated in GST-P-negative HAF, HCA, and HCC induced not only by peroxisome proliferators but also N-nitrosodiethylamine alone.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP44615.RAHJ1327nq7gJkn0H6TG4JJgyI8evpg76sOFVjy2uXU_k130_provenance.
- assertion description "[Forty percent of plasma LCAT-HDL was associated with alpha(2)M; moreover, most of the LCAT in cerebrospinal fluid and in the medium of cultured human hepatoma cell line was associated with alpha(2)M. Purified recombinant human LCAT (rLCAT) labeled with (125)I bound to native and methylamine-activated alpha(2)M (alpha(2)M-MA) in vitro in a time- and concentration-dependent manner, and this binding did not depend on the presence of lipid. rLCAT bound to alpha(2)M-MA with greater affinity than to alpha(2)M. Furthermore, rLCAT did not activate alpha(2)M as phosphatidylcholine-specific phospholipase C does.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Forty percent of plasma LCAT-HDL was associated with alpha(2)M; moreover, most of the LCAT in cerebrospinal fluid and in the medium of cultured human hepatoma cell line was associated with alpha(2)M. Purified recombinant human LCAT (rLCAT) labeled with (125)I bound to native and methylamine-activated alpha(2)M (alpha(2)M-MA) in vitro in a time- and concentration-dependent manner, and this binding did not depend on the presence of lipid. rLCAT bound to alpha(2)M-MA with greater affinity than to alpha(2)M. Furthermore, rLCAT did not activate alpha(2)M as phosphatidylcholine-specific phospholipase C does.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Alpha-2-macroglobulin (alpha 2-M), a serum protease inhibitor that also binds cytokines, neutralized the inhibitory effect exerted by transforming growth factor-beta (TGF-beta) on IL-6-induced C-reactive protein (CRP) production by the human hepatoma cell line PLC/PRF/5. alpha 2-M was found to bind noncovalently with TGF-beta to form a complex that, upon acidification, released TGF-beta inhibitory activity as detected by IL-6-induced CRP production.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Since elevated TGF-beta1 promotes the development of many tumour types, these observations suggest that the HBxAg-mediated alteration in TGF-beta1 and alpha(2)-M production may contribute importantly to the pathogenesis of HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP916395.RAkjiXJD1mZGuLCagZ8ls_Cpru0gGlnEerAzMcBNDcdHo130_assertion description "[Since elevated TGF-beta1 promotes the development of many tumour types, these observations suggest that the HBxAg-mediated alteration in TGF-beta1 and alpha(2)-M production may contribute importantly to the pathogenesis of HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP916395.RAkjiXJD1mZGuLCagZ8ls_Cpru0gGlnEerAzMcBNDcdHo130_provenance.
- NP217273.RAjJPK6HV6-BB6rSHeSK1xzVatbwhk_C0RJEAh3JbnVz0130_assertion description "[Since elevated TGF-beta1 promotes the development of many tumour types, these observations suggest that the HBxAg-mediated alteration in TGF-beta1 and alpha(2)-M production may contribute importantly to the pathogenesis of HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217273.RAjJPK6HV6-BB6rSHeSK1xzVatbwhk_C0RJEAh3JbnVz0130_provenance.
- NP430960.RApIV1LpKFDJUopNB9Kjq-HU4Pb0vQ99ik2-omszhgdUw130_assertion description "[Since elevated TGF-beta1 promotes the development of many tumour types, these observations suggest that the HBxAg-mediated alteration in TGF-beta1 and alpha(2)-M production may contribute importantly to the pathogenesis of HCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP430960.RApIV1LpKFDJUopNB9Kjq-HU4Pb0vQ99ik2-omszhgdUw130_provenance.
- NP31562.RA-SQnrGu8DtiE7hdSA9Y7nUGh74SfwvLikuuLLliXy7I130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31562.RA-SQnrGu8DtiE7hdSA9Y7nUGh74SfwvLikuuLLliXy7I130_provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP17137.RAtKHL3dkIwNYzBJ5bYh2jhQw-9PLTcqHtF9-JppXVAjM130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP17137.RAtKHL3dkIwNYzBJ5bYh2jhQw-9PLTcqHtF9-JppXVAjM130_provenance.
- NP21390.RA6uhaZhMttBVMjjpBoUizwy1MQBigt4uSNiD77KV7CQ8130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP21390.RA6uhaZhMttBVMjjpBoUizwy1MQBigt4uSNiD77KV7CQ8130_provenance.
- NP32403.RApf-mOI7ui7ytA1Mh1USITV-lue7EbHPA4gDjXhsCQK4130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32403.RApf-mOI7ui7ytA1Mh1USITV-lue7EbHPA4gDjXhsCQK4130_provenance.
- NP17638.RAHm5DZFYjKV1OGv8kkGYDGQ7n3DnMb2nMHD1qcoVvOTk130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP17638.RAHm5DZFYjKV1OGv8kkGYDGQ7n3DnMb2nMHD1qcoVvOTk130_provenance.
- NP7170.RAiIoJByO7lBCS30YjUFTHdmI1RLEUw0dsTXHTFDWCS7c130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP7170.RAiIoJByO7lBCS30YjUFTHdmI1RLEUw0dsTXHTFDWCS7c130_provenance.
- NP11235.RALZkUvGD_ymf8rtsbSulY8i5Gz7uV0JT5L3gLCsjVnXc130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP11235.RALZkUvGD_ymf8rtsbSulY8i5Gz7uV0JT5L3gLCsjVnXc130_provenance.
- NP12053.RAHOVgvg2Py-Ek3jaQMxpv4w2PZBnUwlKu1jClL4cuCu8130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12053.RAHOVgvg2Py-Ek3jaQMxpv4w2PZBnUwlKu1jClL4cuCu8130_provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP20760.RAcfWVkq70HGLOss43gaxdntvro4lnDzTLgLeoAFIdetk130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP20760.RAcfWVkq70HGLOss43gaxdntvro4lnDzTLgLeoAFIdetk130_provenance.
- NP32843.RAc6t0juQAOEMAn3xO3Vu7cfgizz758mfhlUbo5JF1DII130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP32843.RAc6t0juQAOEMAn3xO3Vu7cfgizz758mfhlUbo5JF1DII130_provenance.
- NP16179.RAa2SFd4uZFhJxA0Tq_DSJfbbPyAoFfXHUEF_aFGztYAk130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP16179.RAa2SFd4uZFhJxA0Tq_DSJfbbPyAoFfXHUEF_aFGztYAk130_provenance.
- NP5241.RA4DkJnUPwL_dsggc21jzZ2RbWjnr8VLjHXrEhHltL-KQ130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP5241.RA4DkJnUPwL_dsggc21jzZ2RbWjnr8VLjHXrEhHltL-KQ130_provenance.
- NP10627.RA5mLpwsEs7cToos6yiCZ1jy9Mswzs04L_DUNUXAhzhUQ130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP10627.RA5mLpwsEs7cToos6yiCZ1jy9Mswzs04L_DUNUXAhzhUQ130_provenance.
- NP16718.RAgICe3uvX2_GRc9WoO_oRzAoRYvY_K7FXEe7emUdWO4Q130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP16718.RAgICe3uvX2_GRc9WoO_oRzAoRYvY_K7FXEe7emUdWO4Q130_provenance.
- NP31925.RAyuHGUmplIi3xACjxQQrCpZ53Wp60Li0xi0NABbv0Va8130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31925.RAyuHGUmplIi3xACjxQQrCpZ53Wp60Li0xi0NABbv0Va8130_provenance.
- NP9735.RAiyqQQNuV9ECtt29EBUQ2_dYPrzqDQMgTLntVjS1kHpU130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP9735.RAiyqQQNuV9ECtt29EBUQ2_dYPrzqDQMgTLntVjS1kHpU130_provenance.
- NP31899.RAT7iiqcL8EHjkXuD3Lkrct8tpo5bGiO47bHomgq3VzZE130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31899.RAT7iiqcL8EHjkXuD3Lkrct8tpo5bGiO47bHomgq3VzZE130_provenance.
- NP31900.RARYGh2Afmf7VGvdWJUjq0H8Gxl_X75aQ4FPtG7td8d0g130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31900.RARYGh2Afmf7VGvdWJUjq0H8Gxl_X75aQ4FPtG7td8d0g130_provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP31893.RAmqKb8j9T7fPXKh2N_lXVA4Jp7LKIjvh2y3TIp4pu34E130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31893.RAmqKb8j9T7fPXKh2N_lXVA4Jp7LKIjvh2y3TIp4pu34E130_provenance.
- NP31896.RAiAl6HpNbRdwTvhBpbadccNmrjCzL8vYrrcq1i6rFWV8130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31896.RAiAl6HpNbRdwTvhBpbadccNmrjCzL8vYrrcq1i6rFWV8130_provenance.
- NP31897.RAkG8iAHm3omb0YLu4PpfzbbwOdn7rLc3J9jnYYoNbgVY130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31897.RAkG8iAHm3omb0YLu4PpfzbbwOdn7rLc3J9jnYYoNbgVY130_provenance.
- NP31898.RAn3VFYTN_KeQWPaQFMHJG0ACioq6dneRc1CmvE0-Iqq0130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31898.RAn3VFYTN_KeQWPaQFMHJG0ACioq6dneRc1CmvE0-Iqq0130_provenance.
- NP31894.RAGRMZCky7Jv9G54R_W793GJcESfBZZf1_712P9KaIZOU130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31894.RAGRMZCky7Jv9G54R_W793GJcESfBZZf1_712P9KaIZOU130_provenance.
- NP31895.RA-MV4Es0W6g46Od1CDDspYt3O67IUQ0O9e7Q5LATEuhA130_assertion description "[Repeat oral dose toxicity studies of melamine in rats and monkeys.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP31895.RA-MV4Es0W6g46Od1CDDspYt3O67IUQ0O9e7Q5LATEuhA130_provenance.
- assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP381641.RAXasEdkJrX9MZTKKk0Kxnrjqvw0gHovS0rhTNTQJau-A130_assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP381641.RAXasEdkJrX9MZTKKk0Kxnrjqvw0gHovS0rhTNTQJau-A130_provenance.
- NP381642.RAv2uWAdbX8Krwq5l-0yjmBTOIWCdd703c_ALlnKWWW-E130_assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP381642.RAv2uWAdbX8Krwq5l-0yjmBTOIWCdd703c_ALlnKWWW-E130_provenance.
- NP217223.RA0P3pLf6wMG9nC5EyCKWQP_yy-MslZXdzcvM74HyibC8130_assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217223.RA0P3pLf6wMG9nC5EyCKWQP_yy-MslZXdzcvM74HyibC8130_provenance.
- NP637355.RA2DXzWlvXMzHZcAi4dHrx6rV76EDNs0_mv-R9nDktQX8130_assertion description "[Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands such as fatty acids and rosiglitazone increased functional cell surface LRP by 1.5-2.0-fold in primary human adipocytes and in the SW872 human liposarcoma cell line as assessed by activated alpha(2)-macroglobulin binding and degradation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP637355.RA2DXzWlvXMzHZcAi4dHrx6rV76EDNs0_mv-R9nDktQX8130_provenance.
- assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP122882.RAT_Rr92zs0_dExuwx3YsrrfJBxj0FQQVCMeCippeODBo130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP122882.RAT_Rr92zs0_dExuwx3YsrrfJBxj0FQQVCMeCippeODBo130_provenance.
- NP130177.RAQYzSULBzpyraknvnOhKZhRacUxGHUF5AKNF_3D8MgEk130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130177.RAQYzSULBzpyraknvnOhKZhRacUxGHUF5AKNF_3D8MgEk130_provenance.
- NP130206.RAZnIKc_d5ldQdyNdbieL9ownf2Bu6sdq3ZzY3BNsbrBY130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130206.RAZnIKc_d5ldQdyNdbieL9ownf2Bu6sdq3ZzY3BNsbrBY130_provenance.
- NP130261.RAYCEY9bAtZbT2rwvuICZR7uuE9N6pW-C94Vfx7bmPoz4130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130261.RAYCEY9bAtZbT2rwvuICZR7uuE9N6pW-C94Vfx7bmPoz4130_provenance.
- NP130283.RAZAhH10Scayuq9T_juX5_529jy0l119AtNctEXOHfJPM130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130283.RAZAhH10Scayuq9T_juX5_529jy0l119AtNctEXOHfJPM130_provenance.
- NP130310.RAfv5PzU9lnMWYcK9RpWGkosqmfW9sXuPEXZDE2U1bD04130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130310.RAfv5PzU9lnMWYcK9RpWGkosqmfW9sXuPEXZDE2U1bD04130_provenance.
- NP130340.RAa0UpP16oKKuJ119d5uC-rhRMG9Q-DILiFFsWXqLdvxA130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130340.RAa0UpP16oKKuJ119d5uC-rhRMG9Q-DILiFFsWXqLdvxA130_provenance.
- NP130374.RAQX7HRBDB8KQ6CIaQ4_1MU_RSrBcYO5kf5Wy3tAXLQS4130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP130374.RAQX7HRBDB8KQ6CIaQ4_1MU_RSrBcYO5kf5Wy3tAXLQS4130_provenance.
- NP131484.RAVOycZ5yz0GurucqNMQxIy9JsMi50Hmcye-at6lvMjBc130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131484.RAVOycZ5yz0GurucqNMQxIy9JsMi50Hmcye-at6lvMjBc130_provenance.
- NP131487.RARyhQIku8hLHIeA5wlfMARrOiMOp7uBfBHuvjLRzA11g130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP131487.RARyhQIku8hLHIeA5wlfMARrOiMOp7uBfBHuvjLRzA11g130_provenance.
- NP132835.RAcgB--wwSm0gwXkOR70iv9EyLs-mHqIH3udHuKELxo64130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP132835.RAcgB--wwSm0gwXkOR70iv9EyLs-mHqIH3udHuKELxo64130_provenance.
- NP147215.RAfPRDz0gyvLMhFpc3dSgwQbSD6rCybwP-eQaOkbSKw0A130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP147215.RAfPRDz0gyvLMhFpc3dSgwQbSD6rCybwP-eQaOkbSKw0A130_provenance.
- NP148855.RAWU3kdTcNC1KTOYY967g3JyzJpxgi4ISC7rrOBZvhanc130_assertion description "[This identification of a cluster of four IFNGR2 variants strongly associated with fibrosis progression in chronic HCV infection underlines the role of IFNgamma in the development of liver fibrosis that may pave the way for new treatments.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP148855.RAWU3kdTcNC1KTOYY967g3JyzJpxgi4ISC7rrOBZvhanc130_provenance.